TY - JOUR
T1 - Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma
AU - Pintarelli, Giulia
AU - Dassano, Alice
AU - Cotroneo, Chiara E.
AU - Galvan, Antonella
AU - Noci, Sara
AU - Piazza, Rocco
AU - Pirola, Alessandra
AU - Spinelli, R.
AU - Incarbone, Matteo Alessio
AU - Palleschi, Alessandro
AU - Rosso, Lorenzo Paolo
AU - Santambrogio, Luigi
AU - Dragani, Tommaso A.
AU - Colombo, Francesca
PY - 2016/5/10
Y1 - 2016/5/10
N2 - Read-through transcripts result from the continuous transcription of adjacent, similarly oriented genes, with the splicing out of the intergenic region. They have been found in several neoplastic and normal tissues, but their pathophysiological significance is unclear. We used high-throughput sequencing of cDNA fragments (RNA-Seq) to identify read-through transcripts in the non-involved lung tissue of 64 surgically treated lung adenocarcinoma patients. A total of 52 distinct read-through species was identified, with 24 patients having at least one read-through event, up to a maximum of 17 such transcripts in one patient. Sanger sequencing validated 28 of these transcripts and identified an additional 15, for a total of 43 distinct read-through events involving 35 gene pairs. Expression levels of 10 validated read-through transcripts were measured by quantitative PCR in pairs of matched non-involved lung tissue and lung adenocarcinoma tissue from 45 patients. Higher expression levels were observed in normal lung tissue than in the tumor counterpart, with median relative quantification ratios between normal and tumor varying from 1.90 to 7.78; the difference was statistically significant (P <0.001, Wilcoxon's signed-rank test for paired samples) for eight transcripts: ELAVL1-TIMM44, FAM162B-ZUFSP, IFNAR2-IL10RB, INMT-FAM188B, KIAA1841-C2orf74, NFATC3-PLA2G15, SIRPB1-SIRPD, and SHANK3-ACR. This report documents the presence of read-through transcripts in apparently normal lung tissue, with inter-individual differences in patterns and abundance. It also shows their down-regulation in tumors, suggesting that these chimeric transcripts may function as tumor suppressors in lung tissue.
AB - Read-through transcripts result from the continuous transcription of adjacent, similarly oriented genes, with the splicing out of the intergenic region. They have been found in several neoplastic and normal tissues, but their pathophysiological significance is unclear. We used high-throughput sequencing of cDNA fragments (RNA-Seq) to identify read-through transcripts in the non-involved lung tissue of 64 surgically treated lung adenocarcinoma patients. A total of 52 distinct read-through species was identified, with 24 patients having at least one read-through event, up to a maximum of 17 such transcripts in one patient. Sanger sequencing validated 28 of these transcripts and identified an additional 15, for a total of 43 distinct read-through events involving 35 gene pairs. Expression levels of 10 validated read-through transcripts were measured by quantitative PCR in pairs of matched non-involved lung tissue and lung adenocarcinoma tissue from 45 patients. Higher expression levels were observed in normal lung tissue than in the tumor counterpart, with median relative quantification ratios between normal and tumor varying from 1.90 to 7.78; the difference was statistically significant (P <0.001, Wilcoxon's signed-rank test for paired samples) for eight transcripts: ELAVL1-TIMM44, FAM162B-ZUFSP, IFNAR2-IL10RB, INMT-FAM188B, KIAA1841-C2orf74, NFATC3-PLA2G15, SIRPB1-SIRPD, and SHANK3-ACR. This report documents the presence of read-through transcripts in apparently normal lung tissue, with inter-individual differences in patterns and abundance. It also shows their down-regulation in tumors, suggesting that these chimeric transcripts may function as tumor suppressors in lung tissue.
KW - Conjoined genes
KW - Gene fusion
KW - Lung adenocarcinoma
KW - Read-through transcripts
KW - RNA-Seq
UR - http://www.scopus.com/inward/record.url?scp=84968861323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84968861323&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.8556
DO - 10.18632/oncotarget.8556
M3 - Article
SN - 1949-2553
VL - 7
SP - 27889
EP - 27898
JO - Oncotarget
JF - Oncotarget
IS - 19
ER -